2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

622. Lymphomas: Translational – Non-Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Monoclonal Antibody Therapy, Biological Processes, Pathogenesis, Genomics, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1774 Engineering a patient-derived vascularized follicular lymphoma-on-chip to model tumor–microenvironment crosstalk and therapeutic response

Noelia Sandoval-Hellín, N/A, Marina Fortea, PhD2, Ruben Gimenez, PhD3, Farid Seral4, Isobel Taylor-Hearn, PhD5, Neus Serrat, PhD6, Ferran Araujo-Ayala, PhD7, Armando Lopez-Guillermo, MD, PhD8, Elias Campo, MD, PhD9, Sonia Guedan, PhD10, Kristina Haase, PhD11, Patricia Perez Galan, PhD12
1 Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS), Barcelona, Spain
2 EMBL Barcelona, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain
3 Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS), Barcelona, Spain
4 EMBL Barcelona, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain
5 EMBL Barcelona, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain
6 Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS), Barcelona, Spain
7 University College of London, London, United Kingdom
8 Hospital Clínic de Barcelona, Barcelona, Spain
9 Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS), Barcelona, Spain, Hospital Clínic de Barcelona, Barcelona, Spain
10 Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS), Barcelona, Spain
11 EMBL Barcelona, Parc de Recerca Biomèdica de Barcelona, Barcelona, Spain
12 Centro de Investigación Biomédica en Red-Oncología (CIBERONC), Madrid, Spain, Fundació de Recerca Clínic Barcelona-Institut d'Investigacions Biomèdiques August Pi Sunyer (FRCB-IDIBAPS), Barcelona, Spain

Follicular lymphoma (FL) is an indolent but relapsing B-cell malignancy accounting for approximately 20–30% of all non-Hodgkin lymphomas. Despite major therapeutic advances, FL remains largely incurable due to frequent relapse and its strong dependence on the tumor microenvironment (TME). We previously developed a patient-derived follicular lymphoma tumoroid (PDLT) (Gimenez R, Blood (2024) 144 (suppl 1): 1613), that recapitulates key tumor–immune interactions. However, this system is limited by a short lifespan (7 days) and lacks a functional perfusable vascular niche. Vascularization is a key feature of FL and is related to histological transformation (tFL) into aggressive lymphoma (Farinha P, et al. Haematologica. 2010;95(12):2157-2160) where vascular remodeling affects immune cell recruitment and cell therapies delivery, as demonstrated in aggressive lymphoma mouse models (Menzel L, Cell Rep. 2021 Oct 26;37(4):109878). Therefore, physiologically relevant vascularized patient-derived models are needed to support long-term culture, better reproduce the native TME and transformation setting, and enable robust therapeutic evaluation.

Here, we have developed a vascularized follicular lymphoma-on-chip model by integrating patient-derived FL tumoroids with functional, tonsil-like microvasculature in a microfluidic device. The engineered vascular network becomes perfusable from day 5 and supports B-cell survival for up to 10 days, substantially extending the experimental window compared with conventional PDLT cultures. Vascularization also enhanced overall cell viability in both FL tumoroids and reactive lymph node controls, highlighting the essential role of a functional vascular niche in tissue homeostasis.

To investigate the impact of disease aggressiveness on vascular function, we generated vascularized FL models from PDLTs containing a stromal compartment representative of either an indolent (iTME) or transformed/aggressive (tTME) microenvironment. Functional analysis revealed a marked disruption of vascular barrier integrity exclusively in the tTME condition (p < 0.0001), whereas the iTME condition induced only modest changes in vascular permeability. These findings indicate that aggressive lymphoma-derived microenvironments more profoundly impair endothelial function, potentially through extracellular matrix remodeling and altered tumor–stroma interactions. However, the absence of major vascular morphological changes suggests that endothelial dysfunction precedes overt vascular remodeling.

Furthermore, single-cell RNA sequencing analysis is underway to characterize the cellular complexity of the model.  By comparing non-tumoral controls with FL samples exposed to iTME or tTME, we aim to define changes in malignant B cells, endothelial cells, stromal cells and other non-malignant populations. These analyses will reveal how indolent and transformed microenvironments influence cellular composition, transcriptional states and tumor–vascular interactions, providing a comprehensive atlas of patient-specific microenvironmental remodeling associated with disease progression.

Beyond modeling FL biology, we aim to offer this vascularized model as a preclinical tool for evaluating emerging therapeutic strategies within a physiologically relevant microenvironment. As proof of concept, we are assessing the effects of standard-of-care therapies, including rituximab and lenalidomide, together with next-generation immunotherapies such as CD19 CAR T-cell therapy, on tumor architecture, vascular integrity and cellular interactions.

Overall, we present a vascularized follicular lymphoma-on-chip model that faithfully recreates key features of the FL microenvironment while incorporating a functional, perfusable vascular niche. By enabling prolonged culture, vascular perfusion, tumor cell migration through blood vessels, and high-resolution characterization of tumor and stromal compartments, this system provides a physiologically relevant platform for studying FL biology and tumor–vascular crosstalk in both indolent and transformed settings. More importantly, it offers a versatile patient-specific platform for evaluating current and emerging therapies, with the potential to accelerate preclinical drug development while reducing animal experimentation.

Noelia Sandoval-Hellín, N/A: No relevant conflicts of interest to declare.